Beaufour Ipsen Pharma SAS

Feb. 06, 2024 -- Linnea SA, a leading global Active Pharmaceutical Ingredients manufacturer with over 40 years of experience and a long-term presence in the Latam area, is pleased to announce the start of a strategic partnership with the Universidade Estadual de Campinas (UniCamp), a prestigious public research university in the state of São Paulo, Brazil. This important partnership aims to streamline and advance scientific development and research into cannabinoids. The cannabinoid market in Latin America has been growing over the last years as a result of patients' demand for safe, reliable and effective therapy. The current cannabinoid delivery forms are often not aligned with the standards of quality typical of the pharmaceutical world and necessary to ensure the safety and the efficacy for patients. As the demand for cannabinoid therapies rises, health authorities are gradually creating rules to protect consumers and help healthcare personnel to identify the best cannabinoid treatments. To help accelerate this process, Linnea SA and Unicamp are now working together on the development of innovative cannabinoid-based products in alignment with current and future medical needs. Linnea SA and Unicamp believe promoting science through high-quality products can help people to receive better treatments. Linnea SA currently sells their botanical nature derived APIs, including cannabinoids, to over 300 business partners in over 70 different countries worldwide. Linnea SA is proud to promote the best practices and are strongly committed to ongoing scientific research and development through global strategic partnerships. Universidade Estadual de Campinas (Unicamp) is a well respected leading research university that is responsible for around 15% of Brazilian research and also produces more patents than any other research organization in Brazil. Linnea SA has been providing gold-standard botanical ingredients for use in the pharmaceutical, cosmetics and dietary supplement industries for over 40 years. Having expanded into the cannabis and cannabinoid industries in 2016, they helped pave the way in research, standardization and a pharmaceutical level of quality for this emerging global industry. The content above comes from the network. if any infringement, please contact us to modify.

All six companies “admitted their involvement in the cartel and agreed to settle the case,” the European Commission said in a release. Five pharmaceutical companies, including the global player Boehringer Ingelheim, have landed in hot water for running a "cartel" to dominate the market for a specific drug ingredient in Europe. The European Commission (EC) is fining Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea and Transo-Pharm a total of €13.4 million ($14.2 million) to settle claims that the companies agreed to fix prices and allocate business on the pharmaceutical component N-Butylbromide Scopolamine/ Hyoscine (SNBB), which is used to make the decades-old abdominal antispasmodic Buscopan and its generics. Boehringer received the largest fine by far, settling with the EC for €10.4 million. A spokesperson for Boehringer said the company "accepts the settlement decision and remains committed to fair competition, integrity, and compliance." "We have a zero-tolerance policy for any illegal or illicit business practices and are dedicated to always doing the right thing," the spokesperson added. Notably, C2 Pharma—which prides itself on tackling human rights, labor, the environment and corruption—has dodged all fines for blowing the whistle on the cartel to the EC. All six companies “admitted their involvement in the cartel and agreed to settle the case,” the European Commission said in a press release. The companies were accused of conspiring to fix the minimum sales price of SNBB, allocating quotas and exchanging “commercially sensitive” information, the EC said. The behavior ran from late 2005 to Sept. 17, 2019, according to authorities. Notably, Boehringer stopped its participation in the cartel at the end of 2014, with whistleblower C2 Pharma calling it quits in February of 2016. The EC said this is the first time it’s sanctioned a pharmaceutical cartel over an active pharmaceutical ingredient (API). The agency worked in tandem with Swiss and Australian competition authorities to level the charges. A seventh company, Alchem, is also being investigated but decided not to settle. Proceedings against that company will continue in tandem with Europe’s cartel procedure, the EC said.

The European Commission on Thursday announced a first for its regulation of the pharma industry: It’s fining five pharma companies — Alkaloids of Australia, Alkaloids Corporation, Boehringer Ingelheim, Linnea and Transo-Pharm — €13.4 million ($14.2 million) for colluding to fix the price of a pharmaceutical ingredient used in a drug to treat stomach cramps. The Commission said its investigation revealed that six companies — the sixth company C2 Pharma revealed the price fixing to the Commission and was not fined — coordinated and agreed to fix the minimum sales price of the ingredient, known as N-butylbromide scopolamine/hyoscine, which is commonly used in the antispasmodic drug Buscopan as well as in its generic versions. The ingredients were shipped to customers such as distributors and generic drugmakers, and the companies collaborated to allocate quotas.